The exposure of autocrine growth regulated human tumor cells to therapeutically applied doses of ionizing radiation activates ERBB and other receptor Tyr kinases. Details of these responses, including the simultaneous activation of the compliment of ERBB receptors on a cell and downstream signaling along major existing pathways, have been described by our group. The activation of ERBB1 is characterized by a biphasic increase in Tyr phosphorylation, the primary response occurring within 1-5 min, whereas the later phase is seen between 60 and 240 min, possibly mediated by TGF-alpha release as the result of the initial activation. Relative to growth factors, e.g., EGF as ligand for ERBB1, radiation induces a less intense response at the receptor level; however, at the level of cytoplasmic protein kinases the signals are of identical intensity. The biphasic activation of ERBB1 and the simultaneous activation of all ERBB receptors, expressed at widely varied concentration by tumor cells, represent fundamental differences in radiation- and growth factor-induced receptor activation and form the basis of the continuation application. We expect to unravel the unique mechanisms of radiation ERBB activation and downstream signaling by identifying the Tyr phosphorylation patterns of ERBBI using proteomics technology (mass spectroscopy phosphopeptide identification) and kinase and dominant negative receptor inhibitors of ERBB1 and its heterodimerization partner ERBB2. The overall objectives are addressed in three Specific Aims (SAs). SAI: The detailed ERBB1 Tyr phosphorylation pattern is defined in stably transfected CHO.ERBB1 cells after exposure to radiation and TGF-alpha. If feasible, ERBB1 is enriched in the plasma and the endosomal membranes to examine possible changes in Tyr phoshorylation during receptor processing. ERBB1 Tyr phosphorylation is examined as a function of receptor homo- and heterodimedzation through studies on interactions with ERBB2 and dominant negative ERBB1-CD533. SA2: ERBB1 Tyr phosphorylation is correlated with the formation of receptor protein signaling complexes, including studies with the Tyr-Phe ERBB1 mutation to affirm the functional importance of individual Tyr residues. SA3.
This aim addresses the mechanisms underlying the immediate and simultaneous activation of ERBB receptors by investigating the potential role of protein Tyr phosphatases, known to interact with ERBBI, in controlling the quiescent steady state Tyr phosphorylation of ERBB1 and its processing with the cellular membranes.
|Cardnell, Robert J G; Mikkelsen, Ross B (2011) Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One 6:e20147|
|Yakovlev, Vasily A; Barani, Igor J; Rabender, Christopher S et al. (2007) Tyrosine nitration of IkappaBalpha: a novel mechanism for NF-kappaB activation. Biochemistry 46:11671-83|
|Contessa, Joseph N; Abell, Angela; Mikkelsen, Ross B et al. (2006) Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res Treat 95:17-27|
|Barrett, Daniel M; Black, Stephen M; Todor, Horia et al. (2005) Inhibition of protein-tyrosine phosphatases by mild oxidative stresses is dependent on S-nitrosylation. J Biol Chem 280:14453-61|
|Sturla, Lisa-Marie; Amorino, George; Alexander, Michael S et al. (2005) Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. J Biol Chem 280:14597-604|
|Lammering, Guido; Valerie, Kristoffer; Lin, Peck-Sun et al. (2004) Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72:267-73|
|Lammering, Guido; Hewit, Theodore H; Holmes, Mathew et al. (2004) Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 10:6732-43|
|Amorino, George P; Mikkelsen, Ross B; Valerie, Kristoffer et al. (2003) Dominant-negative cAMP-responsive element-binding protein inhibits proliferating cell nuclear antigen and DNA repair, leading to increased cellular radiosensitivity. J Biol Chem 278:29394-9|
|Holmes, Matthew; Rosenberg, Elizabeth; Valerie, Kristoffer (2003) Adenovirus expressing p53. Methods Mol Biol 234:1-16|
|Schmidt-Ullrich, Rupert K; Contessa, Joseph N; Lammering, Guido et al. (2003) ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22:5855-65|
Showing the most recent 10 out of 36 publications